Adverse reactions linked to Botox use, warns FDA
Ongoing safety review of Botox, Botox Cosmetic and Myobloc taking place in US. – The U.S. Food and Drug Administration today notified the public that Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B) have been linked in some cases to adverse reactions, including respiratory failure and death, following treatment of a variety of conditions using a wide range of doses.